Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab and Polatuzumab Vedotin in Untreated Follicular Lymphoma
NCT05410418Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2022
- Primary completion
- Sep 2025
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mosunetuzumab and polatuzumab vedotin in follicular lymphoma (FL), sponsored by Washington University School of Medicine. Primary endpoint: Number of Participants With Complete Response as Best Response at 1 year. Started Oct 2022; status: active, not recruiting.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05410418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410418.